Patents by Inventor Richard A. Mumford
Richard A. Mumford has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8283344Abstract: The invention is directed to a method of treating severe neutropenia, and in particular, cyclic neutropenia (CN) or severe congenital neutropenia (SCN), in a patient in need of such treatment comprising: administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 5, 2008Date of Patent: October 9, 2012Assignees: Merck & Co., Inc., University of WashingtonInventors: David C. Dale, Paul E. Finke, Richard A. Mumford, Andranik Andrew Aprikyan
-
Publication number: 20100216761Abstract: The invention is directed to novel azetidinones selected from 2-(S)-[4-(((2-(Dimethylamino)ethyl)ethylamino)carbonyl)phenoxy]-3,3-diethyl-N-[1-(R)-(4-(trifluoromethoxy)phenyl)butyl]-4-oxo-1-azetidin ecarboxamide, 2-(S)-[4-(((2-(Dimethylamino)ethyl)ethylamino)carbonyl)phenoxy]-3,3-diethyl-N-[1-(R)-(4-(trifluoromethyl)phenyl)butyl]-4-oxo-1-azetidinecarboxamide, and analogs thereof, and pharmaceutically acceptable salts thereof, and their use in the treatment of diseases associated with an excess of elastase, including emphysema, bronchial inflammation, chronic bronchitis, cystic fibrosis, acute respiratory distress syndrome, rheumatoid arthritis, osteoarthritis; glomerulonephritis, spondylitis, lupus, psoriasis, atherosclerosis, sepsis, septicemia, shock, myocardial infarction, reperfusion injury, and periodontitis.Type: ApplicationFiled: October 1, 2008Publication date: August 26, 2010Inventors: James B. Doherty, Paul E. Finke, Richard A. Mumford, Kelly M. Treonze
-
Patent number: 7514409Abstract: Compounds of Formula I are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn's disease, multiple sclerosis, asthma, and rheumatoid arthritis.Type: GrantFiled: March 7, 2005Date of Patent: April 7, 2009Assignee: Merck & Co., Inc.Inventors: William K. Hagmann, Linus S. Lin, Ping Liu, Richard A. Mumford, Thomas S. Reger, Nicholas D. Smith, Nicholas S. Stock, Jasmine Zunic
-
Publication number: 20070179190Abstract: Compounds of Formula I are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn's disease, multiple sclerosis, asthma, and rheumatoid arthritis.Type: ApplicationFiled: March 7, 2005Publication date: August 2, 2007Applicant: MERCK & CO., INC.Inventors: William Hagmann, Linus Lin, Ping Liu, Richard Mumford, Thomas Reger, Nicholas Smith, Nicholas Stock, Jasmine Zunic
-
Patent number: 6943180Abstract: Compounds of formula (I) are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, rhinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.Type: GrantFiled: March 15, 2002Date of Patent: September 13, 2005Assignee: Merck & Co., Inc.Inventors: George Doherty, Linus S Lin, William K. Hagmann, Ginger Xu-qiang Yang, Linda L. Chang, Shrenik K. Shah, Richard A. Mumford, Theodore Kamenecka
-
Patent number: 6903075Abstract: Compounds of Formula I are antagonists of VLA-4 and/or ?4?7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.Type: GrantFiled: May 28, 1998Date of Patent: June 7, 2005Assignee: Merck & Co., Inc.Inventors: Philippe L. Durette, Malcolm MacCoss, William K. Hagmann, Sander G. Mills, Richard A. Mumford, Jack A. Schmidt, Gail A. Van Riper
-
Patent number: 6855708Abstract: Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.Type: GrantFiled: March 13, 2002Date of Patent: February 15, 2005Assignee: Merck & Co., Inc.Inventors: Linus S. Lin, George Doherty, Shrenik K. Shah, Linda L. Chang, William K. Hagmann, Richard A. Mumford
-
Publication number: 20040102478Abstract: Compounds of formula (I) are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, rhinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.Type: ApplicationFiled: September 17, 2003Publication date: May 27, 2004Inventors: George Doherty, Linus S Lin, William K Hagmann, Ginger Xu-qiang Yang, Linda L Chang, Shrenik K Shah, Richard A Mumford
-
Patent number: 6645939Abstract: &bgr;-Alanine derivatives of Formula I are antagonists of VLA-4 and/or &agr;4&bgr;7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.Type: GrantFiled: May 24, 1999Date of Patent: November 11, 2003Assignee: Merck & Co., Inc.Inventors: Philippe L. Durette, William K. Hagmann, Ihor E. Kopka, Malcolm MacCoss, Sander G. Mills, Richard A. Mumford, Plato A. Magriotis
-
Patent number: 6559174Abstract: Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.Type: GrantFiled: March 13, 2002Date of Patent: May 6, 2003Assignee: Merck & Co., Inc.Inventors: Linus S. Lin, Shrenik K. Shah, Linda L. Chang, William K. Hagmann, Richard A. Mumford
-
Publication number: 20030008861Abstract: Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.Type: ApplicationFiled: March 13, 2002Publication date: January 9, 2003Inventors: Linus S. Lin, George Doherty, Shrenik K. Shah, Linda L. Chang, William K. Hagmann, Richard A. Mumford
-
Publication number: 20020193399Abstract: Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.Type: ApplicationFiled: March 13, 2002Publication date: December 19, 2002Inventors: Linus S. Lin, Shrenik K. Shah, Linda L. Chang, William K. Hagmann, Richard A. Mumford
-
Chromophore containing compounds and their use in determining interleukin-1&bgr; convertase activity
Patent number: 6348570Abstract: Disclosed are novel chromophore containing compounds of Formula I and their use in determining interleukin-1&bgr; convertase (ICE) activity. ICE has been implicated in inflammatory or immune-based diseases of the lung and airways; central nervous system and surrounding membranes; the eyes and ears; joints, bones, and connective tissues; cardiovascular system including the pericardium; the gastrointestinal and urogenital systems; the skin and mucosal membranes.Type: GrantFiled: December 17, 1991Date of Patent: February 19, 2002Assignee: Merck & Co., Inc.Inventors: Kevin T. Chapman, Malcolm Maccoss, Richard A. Mumford, Nancy A. Thornberry, Jeffrey R. Weidner, William K. Hagmann -
Patent number: 6291511Abstract: Compounds of Formula I are antagonists of VLA-4 and/or &agr;4&bgr;7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.Type: GrantFiled: July 22, 1999Date of Patent: September 18, 2001Assignee: Merck & Co., Inc.Inventors: Philippe L. Durette, William K. Hagmann, Malcolm MacCoss, Sander G. Mills, Richard A. Mumford
-
Patent number: 6221888Abstract: Compounds of Formula I are antagonists of VLA-4 and/or &agr;4&bgr;7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.Type: GrantFiled: November 29, 1999Date of Patent: April 24, 2001Assignee: Merck & Co., Inc.Inventors: Philippe L. Durette, William K. Hagmann, Malcolm Maccoss, Sander G. Mills, Richard A. Mumford
-
Patent number: 5766909Abstract: Complementary DNAs (cDNAs) encoding inducible nitric oxide synthase are isolated and purified from a cDNA library prepared from macrophage-like cells activated with interferon gamma and bacterial lipopolysaccharide. The full length cDNAs of at least two isoforms of the enzyme are identified and sequenced.Type: GrantFiled: November 5, 1993Date of Patent: June 16, 1998Assignee: Merck & Co., Inc.Inventors: Qiao-Wen Xie, Carl F. Nathan, Richard A. Mumford, Jimmy Ramos Calaycay
-
Patent number: 5420010Abstract: N-substituted azetidinones are a class of inhibitors of human leukocytes elastase which are known to be useful in the treatment of a wide variety of antiinflammatory and antidegenerative diseases. In inhibiting elastase, the therapeutic agents are shown to form a characteristic stable complex with the enzyme. In the assay disclosed herein, the inhibitor-enzyme complex is advantageously hydrolyzed and specific product(s) of the hydrolysis are measured. The assays are useful in a clinical setting, for determining appropriate dosage and assessing the effectiveness of treatment.Type: GrantFiled: July 30, 1993Date of Patent: May 30, 1995Assignee: Merck & Co., Inc.Inventors: Paul E. Finke, William K. Hagmann, William A. Hanlon, John L. Humes, Wilson B. Knight, Malcolm MacCoss, Richard A. Mumford, Shrenik K. Shah
-
Patent number: 5387504Abstract: Monospecific antibodies are produced which are specific for fragments of the connective tissue protein aggrecan, generated by specific stromelysin cleavage. These monospecific antibodies are used in an assay system to detect polypeptide fragments of aggrecan, produced by the specific cleavage of aggrecan by stromelysin. The presence of aggrecan polypeptide fragments demonstrates stromelysin activity. Elevations of stromelysin occur in osteoarthritis, rheumatoid arthritis, atherosclerotic lesions, gout, inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), certain cancers, joint injuries, and numerous inflammatory diseases. The monospecific antibodies and the assay system are used to quantitate aggrecan polypeptide fragments as a readout of stromelysin activity and to evaluate potential stromelysin inhibitors.Type: GrantFiled: September 30, 1992Date of Patent: February 7, 1995Assignee: Merck & Co., Inc.Inventors: Richard A. Mumford, Michael W. Lark, Ellen B. K. Bayne, Lori A. Hoerrner
-
Patent number: 5276139Abstract: N-substituted azetidinones are a class of inhibitors of human leukocytes elastase which are known to be useful in the treatment of a wide variety of antiinflammatory and antidegenerative diseases. In inhibiting elastase, the therapeutic agents are shown to form a characteristic stable complex with the enzyme. In the radioimmune assay disclosed herein, the inhibitor-enzyme complex is advantageously hydrolyzed and specific product(s) of the hydrolysis are measured. The assays are useful in a clinical setting, for determining appropriate dosage and assessing the effectiveness of treatment.Type: GrantFiled: August 26, 1991Date of Patent: January 4, 1994Assignee: Merck & Co., Inc.Inventors: Paul E. Finke, William K. Hagmann, Richard A. Mumford, Shrenik K. Shah
-
Patent number: 5274080Abstract: Inhibitors of human leukocytes elastase are known to be useful in the treatment of a wide variety of antiinflammatory and antidegenerative diseases. In inhibiting elastase, the therapeutic agents are shown to form a characteristic stable complex with the enzyme. In the radioimmunoassay disclosed herein, the inhibitor-enzyme complex is advantageously hydrolyzed and specific product(s) of the hydrolysis are measured utilizing polyclonal antibodies capable of binding to one or more haptens of formula II ##STR1## wherein M is allyl or n-propyl,Z.sub.1 is(a) 5-benzofuranyl or(b) substituted phenyl wherein the substituent is methyl or ethyloxy.The assays utilizing these antibodies are useful in a clinical setting, for determining appropriate dosage and assessing the effectiveness of treatment.Type: GrantFiled: August 26, 1991Date of Patent: December 28, 1993Assignee: Merck & Co., Inc.Inventors: Malcolm MacCoss, Richard A. Mumford